External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different

scientific article published on 17 December 2019

External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/CJP2.153
P932PMC publication ID7164369
P698PubMed publication ID31849189

P50authorErik ThunnissenQ42770142
Andrew DodsonQ89226273
P2093author name stringDavid Allen
Anthony O'Grady
Keith Miller
Jamie Hughes
Suzanne Parry
Birgit Lissenberg-Witte
Alex Haragan
Emma McClean
P2860cites workExtreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancerQ34989083
Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanomaQ36382143
Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and LaunchQ37708016
Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality CenterQ38197280
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung CancerQ38376439
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinomaQ38742013
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomasQ39623256
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platformsQ41348743
PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative studyQ47103927
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, anQ47642815
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerQ47834638
Microarray as a model for quantitative visualization chemistry.Q47871523
Comparison of Four PD-L1 Immunohistochemical Assays in Lung CancerQ49635725
Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancerQ49916859
PD-L1 IHC in NSCLC with a global and methodological perspectiveQ50127658
Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samplesQ50347895
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.Q52586557
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upQ57051777
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 ProjectQ57272453
How to Validate Predictive Immunohistochemistry Testing in Pathology?: A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung CancerQ57279680
Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection MethodsQ88242252
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upQ90310971
Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimenQ91537629
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape ProjectQ91553291
Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clonesQ91566534
The impact of crosslinking and non-crosslinking fixatives on antigen retrieval and immunohistochemistryQ91976328
In ReplyQ95568790
P433issue2
P304page(s)138-145
P577publication date2019-12-17
P1433published inThe journal of pathology. Clinical researchQ27726530
P1476titleExternal quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different
P478volume6

Search more.